Terms: = Skin cancer AND HOXA13, P31271, 3209, ENSG00000106031, HOX1J, HOX1
5 results:
1. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
[TBL] [Abstract] [Full Text] [Related]
2. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
[TBL] [Abstract] [Full Text] [Related]
3. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
Kakehasi AM; Radominski SC; Baravalle MD; Palazuelos FCI; Garcia-Garcia C; Arruda MS; Curi M; Liu J; Qiao M; Velez-Sanchez P; Vargas JI
Clin Rheumatol; 2023 May; 42(5):1249-1258. PubMed ID: 36715850
[TBL] [Abstract] [Full Text] [Related]
4. Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer.
Wohlfahrt P; Bruthans J; Krajčoviechová A; Šulc P; Linhart A; Filipovský J; Mayer O; Widimský J; Blaha M; Abrahámová J; Cífková R
Eur J Intern Med; 2020 Sep; 79():63-69. PubMed ID: 32534942
[TBL] [Abstract] [Full Text] [Related]
5. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study.
Zenda S; Kawashima M; Nishio T; Kohno R; Nihei K; Onozawa M; Arahira S; Ogino T
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):135-9. PubMed ID: 20950948
[TBL] [Abstract] [Full Text] [Related]
